Pierre Beaurang

Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology and neurology. Dr. Beaurang was most recently CEO and member of the board for Nitrase Therapeutics, a private biotechnology company focused on a novel class of enzymes involved in neurodegenerative disorders and cancer. Previously, Dr. Beaurang served as Chief Business Officer of Nurix Therapeutics (NSDQ: NRIX), where he helped grow the company into a publicly traded, clinical-stage company. During his tenure at Nurix, he established several transformational partnerships with global pharmaceutical companies and was part of the leadership team for the company’s IPO. Dr. Beaurang was part of the founding team of Five Prime Therapeutics (NSDQ: FPRX acquired by Amgen), an oncology and immunology biologics company. While at Five Prime, he established several major platform and product collaborations with pharmaceutical companies and licensed the lead asset that drove the eventual acquisition of the company for $1.9 billion in 2021.

Dr. Beaurang holds a B.A. in Biology and an M.A. in Biotechnology from Boston University, and a Ph.D. in Molecular and Cell Biology from the University of California at Berkeley.